Abstract
Man began to consume cereals approximately 10,000 years ago when hunter-gatherers settled in the fertile golden crescent in the Middle East. Gluten has been an integral part of the Western type of diet ever since, and wheat consumption is also common in the Middle East, parts of India and China as well as Australia and Africa. In fact, the food supply in the world heavily depends on the availability of cereal-based food products, with wheat being one of the largest crops in the world. Part of this is due to the unique properties of wheat gluten, which has a high nutritional value and is crucial for the preparation of high-quality dough. In the last 10 years, however, wheat and gluten have received much negative attention. Many believe that it is inherently bad for our health and try to avoid consumption of gluten-containing cereals; a gluten-low lifestyle so to speak. This is fueled by a series of popular publications like Wheat Belly; Lose the Wheat, Lose the Weight, and Find Your Path Back to Health. However, in reality, there is only one condition where gluten is definitively the culprit: celiac disease (CD), affecting approximately 1% of the population in the Western world. Here, I describe the complexity of the cereals from which gluten is derived, the special properties of gluten which make it so widely used in the food industry, the basis for its toxicity in CD patients and the potential for the development of safe gluten and alternatives to the gluten-free diet.
Journal Section:
Gluten: Friend or Enemy?
References
1.
Shewry P: Wheat. J Exp Bot 2009;60:1537-1553.
2.
Spaenij-Dekking EHA, Kooy Y, Koning F: The Ethiopian cereal tef in celiac disease. N Engl J Med 2005;353:1748-1749.
3.
Sollid LM, Qiao SW, Anderson RP, Gianfrani C, Koning F: Nomenclature and listing of celiac disease relevant gluten T-cell epitopes restricted by HLA-DQ molecules. Immunogenetics 2012;64:455-460.
4.
Shan L, Molberg O, Parrot I, Hausch F, Filiz F, Gray GM, Sollid LM, Khosla C: Structural basis for gluten intolerance in celiac sprue. Science 2002;297:2275-2279.
5.
Vader W, de Ru A, van der Wal Y, Kooy Y, Benckhuijsen W, Mearin L, Drijfhout JW, van Veelen P, Koning F: Specificity of tissue transglutaminase explains cereal toxicity in celiac disease. J Exp Med 2002;195:643-649.
6.
van de Wal Y, Kooy Y, van Veelen P, Pena S, Mearin L, Molberg O, Lundin K, Sollid L, Mutis T, Benckhuijsen W, Drijfhout JW, Koning F: Small intestinal cells of celiac disease patients recognize a natural pepsin fragment of gliadin. Proc Natl Acad Sci USA 1998;95:10050-10054.
7.
Molberg O, McAdam SN, Korner R, Quarsten H, Kristiansen C, Madsen L, Fugger L, Scott H, Noren O, Roepstorff P, Lundin KE, Sjostrom H, Sollid LM: Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease. Nat Med 1998;4:713-717.
8.
Anderson RP, Degano P, Godkin AJ, Jewell DP, Hill AV: In vivo antigen challenge in celiac disease identifies a single transglutaminase-modified peptide as the dominant A-gliadin T-cell epitope. Nat Med 2000;6:337-342.
9.
Arentz-Hansen H, Körner R, Molberg O, Quarsten H, Vader W, Kooy YM, Lundin KEA, Koning F, Roepstorff P, Sollid LM, McAdam SN: The intestinal T cell response to α-gliadin in adult celiac disease is focused on a single deamidated glutamine targeted by tissue transglutaminase. J Exp Med 2000;191:603-612.
10.
Vader W, Kooy Y, van Veelen P, de Ru A, Harris D, Benckhuijsen W, Pena S, Mearin L, Drijfhout JW, Koning F: The gluten response in children with recent onset celiac disease. A highly diverse response towards multiple gliadin and glutenin derived peptides. Gastroenterology 2002;122:1729-1737.
11.
Tye-Din JA, Stewart JA, Dromey JA, Beissbarth T, van Heel DA, Tatham A, Henderson K, Mannering SI, Gianfrani C, Jewell DP, Hill AV, McCluskey J, Rossjohn J, Anderson RP: Comprehensive, quantitative mapping of T cell epitopes in gluten in celiac disease. Sci Transl Med 2010;2:41ra51.
12.
Tjon JM, van Bergen J, Koning F: Celiac disease: how complicated can it get? Immunogenetics 2010;62:641-651.
13.
Abadie V, Sollid LM, Barreiro LB, Jabri B: Integration of genetic and immunological insights into a model of celiac disease pathogenesis. Annu Rev Immunol 2011;29:493-525.
14.
Christophersen A, Ráki M, Bergseng E, Lundin KE, Jahnsen J, Sollid LM, Qiao SW: Tetramer-visualized gluten-specific CD4+ T cells in blood as a potential diagnostic marker for coeliac disease without oral gluten challenge. United European Gastroenterol J 2014;2:268-278.
15.
Vader W, Stepniak D, Bunnik EM, Kooy Y, de Haan W, Drijfhout JW, van Veelen PA, Koning F: Characterization of cereal toxicity for celiac disease patients based on protein homology in grains. Gastroenterology 2003;125:1105-1113.
16.
van de Wal Y, Kooy Y, van Veelen P, Pena S, Mearin L, Papadopulos G, Koning F: Cutting edge: selective deamidation by tissue transglutaminase strongly enhances gliadin-specific T cell reactivity. J Immunol 1998;161:1585-1588.
17.
Molberg O, Uhlen AK, Jensen T, Flaete NS, Fleckenstein B, Arentz-Hansen H, Raki M, Lundin KE, Sollid LM: Mapping of gluten T-cell epitopes in the bread wheat ancestors: implications for celiac disease. Gastroenterology 2005;128:393-401.
18.
Mitea C, Salentijn EM, van Veelen P, Goryunova SV, van der Meer IM, van den Broeck HC, Mujico JR, Monserrat V, Gilissen LJ, Drijfhout JW, Dekking L, Koning F, Smulders MJ: A universal approach to eliminate antigenic properties of alpha-gliadin peptides in celiac disease. PLoS One 2010;5: e15637.
19.
Qiao SW, Ráki M, Gunnarsen KS, Løset GÅ, Lundin KE, Sandlie I, Sollid LM: Posttranslational modification of gluten shapes TCR usage in celiac disease. J Immunol 2011;187:3064-3071.
20.
Qiao SW, Christophersen A, Lundin KE, Sollid LM: Biased usage and preferred pairing of α- and β-chains of TCRs specific for an immunodominant gluten epitope in coeliac disease. Int Immunol 2014;26:13-19.
21.
Broughton SE, Petersen J, Theodossis A, Scally SW, Loh KL, Thompson A, van Bergen J, Kooy-Winkelaar Y, Henderson KN, Beddoe T, Tye-Din JA, Mannering SI, Purcell AW, McCluskey J, Anderson RP, Koning F, Reid HH, Rossjohn J: Biased T cell receptor usage directed against human leukocyte antigen DQ8-restricted gliadin peptides is associated with celiac disease. Immunity 2012;37:611-621.
22.
Petersen J, Montserrat V, Mujico JR, Loh KL, Beringer DX, van Lummel M, Thompson A, Mearin ML, Schweizer J, Kooy-Winkelaar Y, van Bergen J, Drijfhout JW, Kan WT, La Gruta NL, Anderson RP, Reid HH, Koning F, Rossjohn J: T-cell receptor recognition of HLA-DQ2-gliadin complexes associated with celiac disease. Nat Struct Mol Biol 2014;21:480-488.
23.
Petersen J, van Bergen J, Loh K, Kooy-Winkelaar Y, Beringer DX, Thompson A, Bakker SF, Mulder CJ, Ladell K, McLaren JE, Price DA, Rossjohn J, Reid HH, Koning F: Determinants of gliadin-specific T cell selection in celiac disease. J Immunol 2015;194:6112-6122.
24.
Arentz-Hansen H, Fleckenstein B, Molberg Ø, Scott H, Koning F, Jung G, Roepstorff P, Lundin KE, Sollid LM: The molecular basis for oat intolerance in patients with celiac disease. PLoS Med 2004;1:e1.
25.
Janatuinen EK, Pikkarainen PH, Kemppainen TA, Kosma VM, Järvinen RM, Uusitupa MI, Julkunen RJ: A comparison of diets with and without oats in adults with celiac disease. N Engl J Med 1995;33:1033-1037.
26.
Maiuri L, Ciacci C, Ricciardelli I, Vacca L, Raia V, Auricchio S, Picard J, Osman M, Quaratino S, Londei M: Association between innate response to gliadin and activation of pathogenic T cells in coeliac disease. Lancet 2003;362:30-37.
27.
Barone MV, Troncone R, Auricchio S: Gliadin peptides as triggers of the proliferative and stress/innate immune response of the celiac small intestinal mucosa. Int J Mol Sci 2014;15:20518-20537.
28.
Koning F: Celiac disease: across the threshold of tolerance; in Fasano A, Troncone R, Brandski D (eds): Frontiers in Celiac Disease. Pediatric Adolesc Med. Basel, Karger, 2008, vol 12, pp 82-88.
29.
ten Dam M, Van De Wal Y, Mearin ML, Kooy Y, Pena S, Drijfhout JW, Koning F, Van Tol M: Anti-alpha-gliadin antibodies (AGA) in the serum of coeliac children and controls recognize an identical collection of linear epitopes of alpha-gliadin. Clin Exp Immunol 1998;114:189-195.
30.
van Herpen TWJM, Goryunova SV, van der Schoot J, Mitreva M, Salentijn E, Vorst O, Schenk M, van Veelen PA, Koning F, van Soest L, Vosman B, Bosch D, Hamer RJ, Gilissen LJWJ, Smulders MJM: Alpha-gliadin genes from the A, B, and D genomes of wheat contain different sets of celiac disease epitopes. BMC Genomics 2006;7:1.
31.
Spaenij-Dekking L, Kooy-Winkelaar Y, van Veelen P, Drijfhout JW, Jonker H, van Soest L, Smulders MJM, Bosch D, Gilissen LJWJ, Koning F: Natural variation in toxicity of wheat accessions for celiac disease patients. Potential for selection and breeding of non-toxic wheat varieties. Gastroenterology 2005;129:797-806.
32.
Stepniak D, Spaenij-Dekking L, Mitea C, Moester M, de Ru A, Baak-Pablo R, van Veelen P, Edens L, Koning F: Highly efficient gluten degradation with a newly identified prolyl endoprotease: implications for celiac disease. Am J Physiol Gastrointest Liver Physiol 2006;291:G621-G629.
33.
Shan L, Marti T, Sollid LM, Gray GM, Khosla C: Comparative biochemical analysis of three bacterial prolyl endopeptidases: implications for coeliac sprue. Biochem J 2004;383:311-318.
34.
Gass J, Khosla C: Prolyl endopeptidases. Cell Mol Life Sci 2007;64:345-355.
35.
Mitea C, Havenaar R, Drijfhout JW, Edens L, Dekking L, Koning F: Efficient degradation of gluten by a prolyl endoprotease in a gastrointestinal model: implications for celiac disease. Gut 2008;57:25-32.
36.
Tack GJ, van de Water JM, Bruins MJ, Kooy-Winkelaar EM, van Bergen J, Bonnet P, Vreugdenhil AC, Korponay-Szabo I, Edens L, von Blomberg BM, Schreurs MW, Mulder CJ, Koning F: Consumption of gluten with gluten-degrading enzyme by celiac patients: a pilot-study. World J Gastroenterol 2013;19:5837-5847.
37.
Salden BN, Monserrat V, Troost FJ, Bruins MJ, Edens L, Bartholomé R, Haenen GR, Winkens B, Koning F, Masclee AA: Randomised clinical study: Aspergillus niger-derived enzyme digests gluten in the stomach of healthy volunteers. Aliment Pharmacol Ther 2015;42:273-285.
38.
Gass J, Bethune MT, Siegel M, Spencer A, Khosla C: Combination enzyme therapy for gastric digestion of dietary gluten in patients with celiac sprue. Gastroenterology 2007;133:472-480.
39.
Montserrat V, Bruins MJ, Edens L, Koning F: Influence of dietary components on Aspergillus niger prolyl endoprotease mediated gluten degradation. Food Chem 2015;174:440-445.
© 2015 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2015
You do not currently have access to this content.
